The MK886 compound has been identified as a selective inhibitor of PPARα as it prevents conformational change for active complex formation, and it is commonly used in exploring therapeutic targets for NAFLD treatment (31–35). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.